Experimental Optimization of a Plasmonic Surface Biofunctionalization, toward the Bimodal Biosensing and Kinetic Characterization of sPD1
Open Access
- 23 December 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (1) , 1396-1409
Abstract
Soluble PD1 (sPD1) plays a complex role in cancer pathophysiology, reportedly dependent on its interactions with immune checkpoint proteins and therapeutic monoclonal antibodies. Yet, no biosensor platform currently affords simultaneous quantification and kinetic profiling of sPD1–antibody interactions. Here, we introduce a surface plasmon resonance (SPR) refractometric biosensor setup functionalized with nivolumab that integrates direct, label-free quantification and real-time functional analysis of sPD1 in a buffer and human serum. Sensor functionalization strategies and robust regeneration protocols were investigated and optimized. The biosensor achieved a limit of detection of 5 ng/mL (limit of quantification (LOQ) 8.7 ng/mL; dynamic range 8.7 ng/mL to 376 μg/mL) and quantified sPD1 with 93 ± 5% recovery in 1% serum and 62 ± 30% in 10% serum. Kinetic constants (k a ≈ 2.32 × 105 M–1 s–1; k d ≈ 1.03 × 10–3 s–1; K D ≈ 4.66 nM) match literature values for the nivolumab–PD1 interaction. This dual-mode SPR platform represents the first attempt to achieve two distinct analytical functions: (i) quantitative detection of soluble PD-1 (sPD1) and (ii) kinetic characterization of the sPD1–antibody interaction, in a single platform, within biological media. The emergent significance of sPD1 as a liquid biopsy biomarker in immuno-oncologic profiling positions this biosensor setup as a powerful tool for research and potential clinical monitoring of immune checkpoint dynamics.Keywords
This publication has 36 references indexed in Scilit:
- The LOD paradox: When lower isn't always better in biosensor research and developmentBiosensors and Bioelectronics, 2024
- A diagnostic electrochemical aptasensor development for sCD80 protein detection in human serumBiosensors and Bioelectronics, 2023
- Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screeningBiosensors and Bioelectronics, 2023
- Repurposing Fc gamma receptor I (FcγRI, CD64) for site-oriented monoclonal antibody capture: A proof-of-concept study for real-time detection of tumor necrosis factor-alpha (TNF -α)Heliyon, 2023
- SPR/SERS dual-mode plasmonic biosensor via catalytic hairpin assembly-induced AuNP networkBiosensors and Bioelectronics, 2021
- A SERS microfluidic platform for targeting multiple soluble immune checkpointsBiosensors and Bioelectronics, 2019
- PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopyAnalytical Biochemistry, 2018
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinibLung Cancer, 2016
- Structure and hydrogen bonding in aqueous sodium chloride solutions using theoretical water model AB4: Effects of concentrationComputational and Theoretical Chemistry, 2011
- Contribution of the PD‐1 ligands/PD‐1 signaling pathway to dendritic cell‐mediated CD4+ T cell activationEuropean Journal of Immunology, 2006